The licensed indications for Merck Sharp & Dohme's Fosamax (alendronate sodium) tablets have been extended. Fosamax is now additionally indicated for "prevention of osteoporosis in those postmenopausal women considered at risk of developing the disease" and for "treatment of glucocorticoid-induced osteoporosis and prevention of bone loss in men and women considered at risk of developing the disease". For the prevention of osteoporosis in postmenopausal women, the recommended dosage is 5mg once a day. For the treatment and prevention of glucocorticoid-induced osteoporosis in postmenopausal women not receiving hormone replacement therapy with an oestrogen, the recommended dosage is 10mg once a day. For other patients (ie men, premenopausal women and postmenopausal women receiving HRT with an oestrogen) the recommended dosage is 5mg once a day.